Suppr超能文献

外阴癌前哨淋巴结:GROningen INternational Study on Sentinel nodes in Vulvar cancer (GROINSS-V) I 的长期随访结果

Sentinel nodes in vulvar cancer: Long-term follow-up of the GROningen INternational Study on Sentinel nodes in Vulvar cancer (GROINSS-V) I.

机构信息

Department of Obstetrics and Gynaecology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.

Department of Obstetrics and Gynaecology, Erasmus Medical Center, Rotterdam, Netherlands.

出版信息

Gynecol Oncol. 2016 Jan;140(1):8-14. doi: 10.1016/j.ygyno.2015.09.077. Epub 2015 Sep 30.

Abstract

OBJECTIVE

In 2008 GROINSS-V-I, the largest validation trial on the sentinel node (SN) procedure in vulvar cancer, showed that application of the SN-procedure in patients with early-stage vulvar cancer is safe. The current study aimed to evaluate long-term follow-up of these patients regarding recurrences and survival.

METHODS

From 2000 until 2006 GROINSS-V-I included 377 patients with unifocal squamous cell carcinoma of the vulva (T1, <4 cm), who underwent the SN-procedure. Only in case of SN metastases an inguinofemoral lymphadenectomy was performed. For the present study follow-up was completed until March 2015.

RESULTS

Themedian follow-up was 105 months (range 0–179). The overall local recurrence ratewas 27.2% at 5 years and 39.5% at 10 years after primary treatment, while for SN-negative patients 24.6% and 36.4%, and for SN-positive patients 33.2% and 46.4% respectively (p = 0.03). In 39/253 SN-negative patients (15.4%) an inguinofemoral lymphadenectomy was performed, because of a local recurrence. Isolated groin recurrence rate was 2.5% for SN-negative patients and 8.0% for SN-positive patients at 5 years. Disease-specific 10-year survival was 91% for SN-negative patients compared to 65% for SN-positive patients (p b .0001). For all patients, 10-year disease-specific survival decreased from 90% for patients without to 69% for patients with a local recurrence (p b .0001).

摘要

目的

2008 年 GROINSS-V-I 是最大的外阴癌前哨淋巴结(SN)程序验证试验,表明在外阴癌早期患者中应用 SN 程序是安全的。本研究旨在评估这些患者的长期随访结果,包括复发和生存情况。

方法

2000 年至 2006 年,GROINSS-V-I 纳入了 377 例单侧局限性外阴鳞癌(T1,<4cm)患者,这些患者均接受了 SN 程序。仅在 SN 转移的情况下才进行腹股沟-股部淋巴结清扫术。本研究的随访时间截至 2015 年 3 月。

结果

中位随访时间为 105 个月(范围 0-179)。原发性治疗后 5 年和 10 年的总局部复发率分别为 27.2%和 39.5%,而 SN 阴性患者的局部复发率分别为 24.6%和 36.4%,SN 阳性患者的局部复发率分别为 33.2%和 46.4%(p=0.03)。在 253 例 SN 阴性患者中,有 39 例(15.4%)因局部复发而行腹股沟-股部淋巴结清扫术。SN 阴性患者的腹股沟复发率为 2.5%,SN 阳性患者的腹股沟复发率为 8.0%,5 年时分别为 2.5%和 8.0%。SN 阴性患者的 10 年疾病特异性生存率为 91%,而 SN 阳性患者为 65%(p<0.0001)。对于所有患者,无局部复发患者的 10 年疾病特异性生存率为 90%,而有局部复发患者的 10 年疾病特异性生存率为 69%(p<0.0001)。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验